ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Reversing Macrophage Immunometabolic Dysfunction in Prolonged Infections Via a Glutaminolysis-Fueled Restoration-Based Hierarchically Selective Therapeutic System.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Prolonged implant-associated bone infection (IBI) fosters an immunosuppressive niche by disrupting the essential immunometabolic reprogramming required for macrophages to support antibacterial immune responses. Mechanistically, our work demonstrates that prolonged infection substantially impairs macrophage immune function by triggering a profound downregulation of glutaminase 1 (GLS1) to stifle glutaminolysis-fueled anaplerosis. Glutaminolysis-fueled dysfunction weakens glutamine-derived mitochondrial reactive oxygen species (mtROS) bursts in macrophages, leading to severe deterioration of IBIs. Herein, we present a hierarchically selective therapeutic system (mGls@HEV-MTP) for glutaminolysis-fueled restoration in macrophages via hierarchical infection-to-macrophage selective GLS1 mRNA delivery. The mGls@HEV-MTP, surface-integrated with mannose-functionalized antibacterial peptide (MTP) via an acid-cleavable hydrazone bond, exploits its acid-responsive property to decorate bacterial surfaces with mannose residues and ensure acid-triggered prerelease of mGls@HEV for selective macrophage uptake in the acidic infection niche. This nano-immunotherapeutic platform orchestrates bactericidal macrophage repolarization by restoring GLS1-driven glutaminolysis-fueled anaplerosis and simultaneously marking invading pathogens with an immune-recognition signal, addressing both immunosuppression and poor immunogenicity in the infection niche. Notably, this work reveals the importance of glutaminolysis-fueled anaplerosis in sustaining macrophage antibacterial immunity and provides a promising immunotherapeutic strategy for IBI eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.